How the Zika virus can infect humans and make them sick is a mystery, but it’s one that could eventually make us sick.
As the world faces the threat of an ongoing pandemic, the CDC is scrambling to figure out how it might infect people in the United States.
To do that, they’re developing a Zika virus that could infect us in an effective way, potentially wiping out people’s immune systems and putting us at risk for a host of other diseases.
The virus that infects the human body is called a zoonotic infection, and it typically doesn’t cause much in the way of symptoms in most people, but when it does, it can be devastating.
In humans, zoonoses can cause a variety of diseases including malaria, Guillain-Barre Syndrome, coronavirus, and a range of viral infections, such as pneumonia and influenza.
The CDC has been studying Zika as a potential vector for a range for some time, but the virus has never been found to be transmitted from person to person.
To find out more, we caught up with Dr. Stephen S. Kosslyn, who heads the CDC’s Center for Vector-Borne Pathogens and is the lead researcher on a study about how Zika might infect humans in the US.
“The goal is to try to isolate a zonal transmission route from a human infection,” Kossyn told us.
“We have a lot of different approaches that have been developed for that.
But one approach that is particularly promising is that we have identified a small, non-transmissible virus that can cause mild disease in humans.
That would be a good starting point to try and isolate a more robust transmission route.
For the last few years, we’ve been studying a novel zoonosis pathogen called CZ-19, which was first identified in a laboratory strain of Zika, and that was one of the first zoonose infections reported in humans in 2015.
But there is currently no zoonodeepsis virus that causes CZ19.
So we’re trying to get an RNA vaccine, which is a way to make an RNA that can target the CZ9 gene in the virus.
Now, we have a vaccine that we are able to get in the field.
This vaccine works like a combination of a flu vaccine, an influenza vaccine, and the current ZIKV vaccine.
So it targets the Cz9 gene that causes mild disease, but also it does not have any side effects.
And we can then look at how that vaccine works, because it’s been shown that it works really well.
We’re going to try it out in the next few months and see how it performs.”
Dr. Krossyn and his team are studying CZ7, the C2C9 protein, which the ZIKvirus and ZIK are targeting, and are currently working to identify the Z-specific CZ17 protein, also known as the C57 gene.
They also are studying the C1-C9 pathway that can lead to the development of a CZ18 protein that could be used in a vaccine.
The C1 protein is the one that causes the most severe zoonosed symptoms, including Guillains-Barré syndrome and other viral infections.
But they also are interested in C1 as a vector for CZ8, which causes Guillans-Barges, a condition in which the virus can cause severe muscle pain and joint inflammation, but which is not a zonotic infection.
The study is focused on C1, and so far, they are only studying it in humans and in animals.
The scientists are also looking at a few other genes that could potentially play a role in CZ16.
It’s also been known for a while that there’s an overlap between CZ and CZ15 in humans, which could lead to an overlap in the C9 pathway, the pathway that could lead into the C15 pathway.
So, they’ve been investigating these pathways for a long time, and this is just the first step of that process.
What the team is interested in, though, is the possibility that this virus might cause a pandemic in the U.S. in the future.
We’ve been looking at the possibility of a pandemic in the States, because the number of cases we’ve seen are rising.
In 2016, we had about 8,700 new cases of the virus in the country.
That’s about the same number that we had in 2013.
So, we’re definitely looking to see if we can identify an increased risk in the coming years.
Kossyn said that the CDC would like to see this study funded so that it could begin testing for ZIK in humans soon.
That’s not a hard deadline, since the current funding level is about $500 million.
But it’s going to be difficult to keep